HomeHealthcare

Technology leadership for healthcare

The clinical decision may be obvious. The technology risk usually is not.

ByrdTail helps HIPAA-regulated and mission-driven healthcare organizations make defensible decisions about AI, vendors, security, technology strategy, and organizational risk.

Where leadership gets involved

HIPAA is part of the question—not the whole answer.

A product can sign a BAA and still be a poor decision. A security checklist can be complete while nobody owns the vendor, the workflow, or the response when something changes.

  1. AI scribes and clinical tools.What data moves, what the vendor retains, how the tool is configured, whether the workflow is appropriate, and who approves continued use.
  2. Vendor and business-associate oversight.Contracts, responsibilities, evidence, recurring reviews, and whether promised controls are actually operating.
  3. Risk analysis leadership.A practical view of exposure, priorities, ownership, and remediation—not a document that disappears until the next audit.
  4. Executive and board communication.Clear decisions, material risks, progress, and tradeoffs in language leaders can act on.

ByrdTail's role

I work above—not instead of—your IT provider.

Your internal team or MSP operates the environment. I connect that work to organizational priorities, compliance obligations, clinical context, and executive accountability.

Before approval

Is this AI tool appropriate for the work?

We look beyond the sales demonstration to the data, contract, workflow, guardrails, users, and decision owner.

After approval

Is the tool still being used the way we intended?

Governance includes an inventory, assigned ownership, staff guidance, vendor changes, incident paths, and periodic review.

When something changes

Who coordinates the humans?

I help align executives, privacy, compliance, counsel, clinical leadership, and IT so the response is owned instead of forwarded indefinitely.

For the board

What do leaders actually need to know?

The decision, material exposure, what is being done, where help is needed, and when the board should hear about it again.